Open

Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypeable Haemophilus influenzae

LA Novotny¹, JD Clements² and LO Bakaletz¹,³

We have developed three nontypeable Haemophilus influenzae (NTHI) adhesin-derived immunogens that are significantly efficacious against experimental otitis media (OM) due to NTHI when delivered parenterally. We now expanded our preventative immunization strategies to include transcutaneous immunization (TCI) as a less invasive, but potentially equally efficacious, regimen to prevent OM due to NTHI. Additionally, we examined the potential of TCI as a therapeutic immunization regimen to resolve ongoing experimental OM. Preventative immunization with NTHI outer membrane protein (OMP) P5- and type IV pilus-targeted immunogens, delivered with the adjuvant LT(R192G-L211A), induced significantly earlier clearance of NTHI from the nasopharynges and middle ears of challenged chinchillas compared with receipt of immunogen or adjuvant alone. Moreover, therapeutic immunization resulted in significant resolution of established NTHI biofilms from the middle ear space of animals compared with controls. These data advocate TCI with the adhesin-directed immunogens as an efficacious regimen for prevention and resolution of experimental NTHI-induced OM.

INTRODUCTION

Nontypeable Haemophilus influenzae (NTHI) is a predominant bacterial agent of the prevalent pediatric disease otitis media (OM), and is also responsible for multiple diseases of the upper and lower respiratory tracts of both children and adults.¹ The economic burden of NTHI-induced diseases, including OM, is significant because of the treatment and surgical management costs.² Complications of OM, for example, hearing loss, are associated with behavioral, educational, and language development delays of this very young population.³ With the goal to prevent NTHI-induced OM, many research efforts have focused on the development of vaccines that target outer membrane proteins (OMPs), other surface proteins, and lipooligosaccharide expressed by this bacterium.⁴ Our lab has concentrated on two of the multiple adhesins expressed by NTHI: OMP P5 and the type IV pilus (Tfp). Specifically, we have designed three vaccine candidates: a 40-mer synthetic chimeric peptide immunogen called “LB1” that incorporates a 19-mer B-cell epitope from OMP P5 that has been colinearly synthesized with a T-cell promiscuous epitope from measles virus fusion protein;⁵ a recombinant protein called “rSPIA” that represents a mature, N-terminally truncated, and soluble PilA subunit protein of the Tfp;⁶ and a chimeric immunogen called “chimV4” in which modified rSPIA serves as both immunogen and carrier molecule for a 24-mer epitope of OMP P5 that is positioned at its N-terminus.⁷ Antibody induced by parenteral immunization with any of these immunogens confers significant protection against NTHI-induced OM in a chinchilla model of viral-bacterial superinfection.⁸ We now wanted to expand our vaccine delivery strategies to develop a noninvasive but potentially equally efficacious method, transcutaneous immunization (TCI).

TCI, the application of a vaccine onto intact skin, induces an immune response by engaging antigen-presenting cells.

¹The Research Institute at Nationwide Children’s Hospital, Department of Pediatrics, Center for Microbial Pathogenesis and The Ohio State University College of Medicine, Columbus, Ohio, USA. ²Department of Microbiology and Immunology, Tulane University Health Sciences Center, New Orleans, Louisiana, USA. ³Nationwide Children’s Hospital, Department of Otolaryngology and The Ohio State University College of Medicine, Columbus, Ohio, USA. Correspondence: LO Bakaletz (Lauren.Bakaletz@NationwideChildrens.org)

Received 30 June 2010; accepted 18 January 2011; published online 16 February 2011. doi:10.1038/mi.2011.6
present within the epidermis and dermis, the Langerhan's cells and dermal dendritic cells (DCs), respectively. There are multiple benefits to this immunization route, which include the simplicity and noninvasive nature of delivery, reduced cost as syringes, needles, and trained medical professionals are not required to deliver the vaccine, and the prospect for greater vaccine distribution beyond developed countries because of typically cheaper production costs. Previous studies show that TCI with bacterial or viral proteins and other peptide antigens induces an immune response in both animals and humans. Furthermore, via use of animal models, there is evidence of protection against subsequent bacterial, viral, or toxin challenge. Whereas parenteral immunization elicits primarily a systemic immune response, TCI induces both systemic and mucosal immunity. OM is a disease of the uppermost respiratory tract, and therefore the ability to induce immunity at the mucosae of this anatomical region has the potential to reduce, or preferably prevent, the onset of disease in the middle ear.

NTHI-induced diseases of the respiratory tract, including OM, can be chronic and/or recurrent in nature, a consequence of biofilms present on the respiratory mucosa. Specific to OM, NTHI biofilms are shown on the middle ear mucosa of children and upon gross examination of the middle ear in animal models. These bacterial communities are recalcitrant to antibiotic treatment and resist immune-mediated clearance. Among other NTHI proteins, OMP P5 and Tfp are identified as components of the biofilm matrix. We therefore hypothesized that immunization with NTHI OMP P5- and Tfp-directed immunogens could serve to target each element in vivo, and thus facilitate resolution of OM. Herein, we utilized a chinchilla model of experimental NTHI-induced OM to examine the immune response elicited by TCI with NTHI OMP P5- and Tfp-directed immunogens when delivered with a potent adjuvant, a double mutant of E. coli heat-labile enterotoxin (dTmLT). Moreover, we examined the efficacy of TCI when utilized in both preventative and therapeutic immunization strategies to determine the potential of this noninvasive approach to protect against as well as resolve experimental NTHI-induced OM.

RESULTS

Histological analysis of chinchilla pinna

Pinnae from naive chinchillas were collected to examine the histological organization of this tissue. A cross-section of a pinna is shown in Figure 1, wherein the epidermis and dermis, supported by elastic connective tissue, were discernible on each side of hyaline cartilage that runs central through the pinna. Similar to human thin skin, the pinna contained hair follicles and sebaceous glands. An abundant stratum corneum was visible as the outermost layer of the epidermis. Therefore, hydration of this keratinized epithelial layer was deemed necessary to enhance the permeability of the skin and thus facilitate both entry of topically applied molecules and sampling by cutaneous antigen-presenting cells, as has been reported.

TCI before NTHI challenge: resolution of nasopharyngeal colonization

To examine the ability of TCI with NTHI OMP P5-directed candidate “LB1,” the Tfp-directed candidate “rsPilA,” and the chimeric OMP P5- plus Tfp-directed immunogen “chimV4,” to induce clearance of NTHI from the nasopharynges (NP) of challenged chinchillas, periodic NP lavages were performed and the recovered fluids cultured to semiquantitate the relative bacterial load at this anatomical site. Cohorts administered any of the three immunogens without adjuvant and the cohort immunized with dLT alone had 10^4–5×10^6 colony-forming unit (CFU) NTHI in NP lavage fluids beginning 3 days after challenge, and maintained this bacterial load for the remainder of the study period (Figure 2a). In contrast, cohorts that received rsPilA, LB1, or chimV4 admixed with dLT demonstrated 2- to 4-log fewer NTHI within NP lavage fluids on each of days 7, 10, and 14 after bacterial challenge, a statistically significant result at each time point, compared with cohorts that received respective immunogen only or dLT only (P<0.05). Moreover, only the three cohorts that received immunogen plus dLT eliminated NTHI from the NP within 10 or 14 days after challenge.

As an additional assessment of efficacy, the relative percentage of animals with culture-positive NP lavage fluids was calculated for each cohort. At 3 days after NTHI challenge, 100% of the animals administered immunogen alone or dLT alone had culture-positive NP lavage fluids, and at least 5/10 (50%) animals in each of these four cohorts remained culture positive for the entire 14-day study period (Figure 2b). In contrast, a 20–40% reduction in culture-positive NP lavage fluids was observed 3 days after NTHI challenge in cohorts that received any of the three tested immunogens plus dLT. Furthermore, at 7 days after NTHI challenge, only 1/10 (10%) animals in the cohorts that received LB1 + dLT or rsPilA + dLT and 4/10 (40%) animals within the cohort administered chimV4 + dLT had culture-positive NP lavage fluids, and by 14 days after bacterial challenge, none of the six cohorts that received immunogen plus dLT had culture-positive NP lavage fluids.
ARTICLES

challenge all of these latter cohorts had eliminated NTHI from the NP. These data therefore demonstrated that TCI with OMP P5- and Tfp-directed candidates, when delivered in combination with dmLT, resulted in an effective immune response that reduced, and then completely eliminated, NTHI from the NP.

TCI before NTHI challenge: resolution of experimental OM
As a more rigorous assessment of the protection afforded by TCI, the same chinchillas as challenged intranasally above were also challenged by direct inoculation of the middle ears with 1,000 CFU NTHI to initiate active OM. Middle ear fluids (MEFs), when present as observed by video otoscopy and confirmed by tympanometry, were collected and cultured to determine the relative concentration of NTHI within these fluids. Within 3 days after challenge, the inoculum of 1,000 CFU NTHI had multiplied to 1.1 × 10^7 CFU NTHI in MEFs retrieved from animals that received dmLT alone (Figure 3a). As 10^8 CFU NTHI is typical for sham-immunized chinchillas (alum or monophosphoryl lipid A), the observed reduction after receipt of dmLT suggested that this adjuvant induced a nonspecific protective effect. Animals administered LB1, rsPilA, or chimV4 alone also exhibited an increase in bacterial concentration to 8.4 × 10^5 – 2.1 × 10^6 CFU NTHI at this time point. Compared with receipt of adjuvant alone, fewer NTHI were detected, which demonstrated that delivery of any of the three immunogens that target NTHI OMP P5 or Tfp induced an enhanced immune response. In contrast, at 3 days after direct challenge, an increase from 1,000 CFU to approximately 8 × 10^3 – 8 × 10^4 CFU NTHI was observed in MEFs collected from animals immunized with any of the three immunogens delivered with dmLT. Moreover, whereas approximately 10^6 to 10^7 CFU NTHI was detected in MEFs collected from animals immunized with only one of three immunogens or with dmLT alone between 7 and 14 days after challenge, significantly fewer NTHI (approximately 2-7-logs

Figure 2  Transcutaneous immunization (TCI) via a preventative regimen induced clearance of nontypeable Haemophilus influenzae (NTHI) from the nasopharynges (NP) of chinchillas. (a) Colonization kinetics that demonstrated that receipt of rsPilA + dmLT, LB1 + dmLT, or chimV4 + dmLT resulted in rapid clearance of NTHI from the NP relative to the cohorts administered rsPilA, LB1, chimV4, or dmLT alone. *Statistically significant compared with receipt of respective immunogen-only cohort and dmLT-alone cohort (P<0.05). CFU, colony-forming unit; dmLT, double mutant of E. coli heat-labile enterotoxin; rsPilA, recombinant soluble PilA. (b) Percentage of colonized NP per cohort showing a reduction in colonization after receipt of LB1 + dmLT, rsPilA + dmLT, or chimV4 + dmLT compared with the cohorts administered rsPilA, LB1, chimV4, or dmLT alone.

Figure 3  Resolution of otitis media (OM) in directly challenged middle ears after immunization via a preventative regimen. (a) Immunization with rsPilA + dmLT, LB1 + dmLT, or chimV4 + dmLT induced clearance of nontypeable Haemophilus influenzae (NTHI) from middle ears of chinchillas compared with the cohorts that received rsPilA, LB1, or chimV4, or the cohort that was immunized with dmLT alone. *Statistically significant compared with receipt of respective immunogen-only cohort or dmLT-alone cohort (P<0.05). CFU, colony-forming unit; dmLT, double mutant of E. coli heat-labile enterotoxin; rsPilA, recombinant soluble PilA. (b) Reduction in the percentage of culture-positive middle ears per cohort after receipt of rsPilA + dmLT, LB1 + dmLT, or chimV4 + dmLT relative to the cohorts that received immunogen or dmLT alone.
less) were observed in MEFs collected from animals immunized with LB1, rsPilA, or chimV4 that had been admixed with dmLT ($P < 0.05$). Notably, animals immunized with chimV4 + dmLT resolved OM within 10 days after challenge.

In terms of the percentage of animals with culture-positive MEFs, similar to that observed in NP lavage fluids, the receipt of rsPilA, LB1, chimV4, or dmLT alone resulted in a minimum of 10/20 ears (50%) with culture-positive MEFs for the entire 14-day study period in all four cohorts (Figure 3b). However, at 3 days after direct challenge of the middle ear, between 80 and 90% of middle ears from animals immunized with any of the three immunogens plus dmLT had resolved OM. At 10 days after challenge, only 1/20 (5%) middle ears in each cohort administered LB1 or rsPilA plus dmLT remained culture positive for NTHI, and those that received chimV4 + dmLT had eliminated the bacterium from the middle ear. Therefore, these data demonstrated that TCI with the NTHI OMP P5- and Tfp-directed candidates delivered with dmLT was efficacious and induced elimination of NTHI from the MEFs of challenged animals as well as rapid resolution of experimental OM.

**TCI before NTHI challenge: analysis of antibody in serum**

To begin to identify the mechanism(s) for the protection observed, we first examined the relative quantity of immunogen-specific antibody produced systemically. TCI with any of the three immunogens alone induced a fourfold increase in the serum antibody geometric mean titer (GMT) of immunogen-specific IgG and a two- to four-fold increase in specific IgA (Table 1) after receipt of all immunizing doses, compared with respective preimmune serum. Inclusion of dmLT in each formulation significantly enhanced the resultant GMT ($P < 0.05$), as a 16- to 64-fold increase in immunogen-specific IgG and a 8- to 16-fold increase in specific IgA was detected relative to preimmune serum. Based on the ability to eradicate NTHI from the NP or middle ear, achieving and maintaining a GMT value of at least 160 for immunogen-specific IgG was associated with most rapid clearance observed here.

**Recognition of native proteins expressed by NTHI by antibody present within NP lavage fluids induced by a preventative immunization regimen**

Whereas TCI with any of the three candidates induced the production of antibody in serum that recognized the immunogen delivered when assayed by enzyme-linked immunosorbent assay, we wanted to determine if antibody produced mucosally, at the site of NTHI colonization, would bind to native structures expressed by viable NTHI, as these structural proteins would be the target for the antibodies during disease. By flow cytometry, 3.5, 3.7, or 1.0% more live, unfixed NTHI were positively labeled by antibody in NP lavage fluids collected after TCI with LB1, rsPilA, or chimV4 alone, respectively, relative to receipt of dmLT alone (Table 2). Incubation of NTHI with immune NP lavage fluids collected from animals immunized with LB1, rsPilA, or chimV4 plus dmLT, however, demonstrated an increase of 12.6, 11.7, or 10.0% in positive labeling of NTHI, respectively, compared with dmLT alone. Relative to fluids collected from animals that received only immunogen, a 3.2- to 10-fold greater labeling of NTHI was achieved when NP lavage fluids from immune animals were assayed, which suggested a greater relative antibody titer and/or greater affinity of the antibody for its target was present within these mucosal secretions. Thus, TCI with the synthetic peptide or recombinant protein immunogens plus dmLT induced the production of mucosal antibody that recognized native structures expressed by NTHI that likely contributed to the rapid bacterial clearance observed.

**Resolution of established NTHI biomass in the middle ear via use of a therapeutic immunization regimen**

To examine the therapeutic potential of TCI with the NTHI OMP P5- and Tfp-directed immunogens, we now first challenged chinchillas by direct inoculation of the middle ear with NTHI strain 86-028NP and allowed a robust biofilm to form in the middle ear space. Previous work has established that when

---

**Table 1** Geometric mean titers of immunogen-specific IgG and IgA in serum after TCI in a preventative immunization regimen

| Cohort          | IgG  | IgA  |
|-----------------|------|------|
| LB1             | 10   | 10   |
| LB1 + dmLT      | 10   | 10   |
| rsPilA          | 10   | 10   |
| rsPilA + dmLT   | 10   | 10   |
| chimV4          | 10   | 10   |
| chimV4 + dmLT   | 10   | 10   |

**Table 2** Recognition of native proteins expressed by NTHI by antibody in NP lavage fluids as assessed by flow cytometry

| Cohort          | Percentage of labeled NTHI (relative to labeling by serum from animals that received dmLT) (%) |
|-----------------|-------------------------------------------------------------------------------------------|
| LB1             | 3.5                                                                                       |
| LB1 + dmLT      | 12.6                                                                                      |
| rsPilA          | 3.7                                                                                       |
| rsPilA + dmLT   | 11.7                                                                                      |
| chimV4          | 1.0                                                                                       |
| chimV4 + dmLT   | 10.0                                                                                      |

**Abbreviations:** dmLT, double mutant of *E. coli* heat-labile enterotoxin; Ig, immunoglobulin; rsPilA, recombinant soluble PilA; TCI, transcutaneous immunization. *$P < 0.05$* compared with respective immunogen-only titer.

---

**Figures and Tables**

Figure 3b: Relative quantity of immunogen-specific antibody produced systemically. TCI with any of the three immunogens alone induced a fourfold increase in the serum antibody GMT (GMT) of immunogen-specific IgG and a two- to four-fold increase in specific IgA (Table 1) after receipt of all immunizing doses, compared with respective preimmune serum. Inclusion of dmLT in each formulation significantly enhanced the resultant GMT ($P < 0.05$), as a 16- to 64-fold increase in immunogen-specific IgG and a 8- to 16-fold increase in specific IgA was detected relative to preimmune serum. Based on the ability to eradicate NTHI from the NP or middle ear, achieving and maintaining a GMT value of at least 160 for immunogen-specific IgG was associated with most rapid clearance observed here.

Table 2: Recognition of native proteins expressed by NTHI by antibody in NP lavage fluids as assessed by flow cytometry.
immunogen-specific IgG was detected in serum from animals after TCI as a therapeutic regimen, predominantly MEFs after immunization by a therapeutic regimen. Induction of immunogen-specific IgG and IgA in serum and MEF after TCI in a therapeutic immunization regimen was achieved after immunization with rsPilA or with chimV4 admixed with dmLT, with GMT that was 4- to 16-times greater compared with that of animals administered respective immunogen alone (Table 3). Within MEFs, again, IgG was the predominant antibody isotype observed, and inclusion of dmLT in each vaccine formulation resulted in a four- to eight-fold increase in specific antibody compared with cohorts administered immunogen alone. Similar to that observed after TCI via a preventative immunization regimen (shown in Table 1), a GMT of ≥160 was associated with enhanced resolution of biomasses within the middle ears. No consistent trend was observed with regard to biomass resolution for immunogen-specific IgA in either serum or MEFs recovered from immune animals. Thus, TCI via a therapeutic immunization regimen induced the production of both systemic and mucosal antibody (primarily IgG), which likely contributed to the observed resolution of NTHI-induced biomass from the middle ear.

**Resolution of MEFs after TCI via a therapeutic immunization regimen**

As an additional and clinically relevant assessment for the resolution of established NTHI-induced OM, each tympanic membrane was observed to document signs of OM before killing. Specifically, video otoscopy and tympanometry were performed and relative signs of inflammation and presence of MEFs behind the tympanic membrane were scored 14 days after NTHI challenge. In the cohort that received dmLT alone, 100% (6/6) of ears were positive for the presence of MEFs (Figure 5). Receipt of LB1 alone or when delivered with dmLT induced a 17–33% reduction in the number of ears with signs of OM, respectively. Moreover, a 33–50% reduction in middle ears with signs of OM was achieved after immunization with rsPilA or with chimV4 alone, respectively. It is noteworthy that immunization via a therapeutic regimen with rsPilA + dmLT resulted in 66% fewer ears with signs of OM, whereas no MEFs were observed behind

**Induction of immunogen-specific IgG and IgA in serum and MEFs after immunization by a therapeutic regimen**

After TCI as a therapeutic regimen, predominantly immunogen-specific IgG was detected in serum from animals using this protocol within 4 days after direct challenge, 83–100% of all middle ears develop a biomass that occupies approximately 75–100% of the middle ear space. Thus, after these biomasses were established, animals were immunized by TCI to determine if the resulting antibodies could resolve these structures. At 1 week after receipt of the second dose, each middle ear was blindly ranked based on a 0 to 4+ scale of relative residual biomass. *Statistically significant compared with receipt of dmLT alone (P<0.05). Receipt of LB1, rsPilA, or chimV4, admixed with dmLT, resulted in significantly enhanced resolution of NTHI biofilms established within the middle ear space. dmLT, double mutant of *E. coli* heat-labile enterotoxin; rsPilA, recombinant soluble PilA.

![Figure 4](image)

**Figure 4** Mean nontypeable *Haemophilus influenzae* (NTHI) biomass scores for each bulla after transcutaneous immunization (TCI) following a therapeutic regimen, based on blinded evaluation and ranked on a 0 to 4+ scale of relative residual biomass. *Statistically significant compared with receipt of dmLT alone (P<0.05). Receipt of LB1, rsPilA, or chimV4, admixed with dmLT, resulted in significantly enhanced resolution of NTHI biofilms established within the middle ear space. dmLT, double mutant of *E. coli* heat-labile enterotoxin; rsPilA, recombinant soluble PilA.

### Table 3 Geometric mean titers of immunogen-specific IgG and IgA in serum and MEF after TCI in a therapeutic immunization regimen

| Cohort       | Immunogen-specific antibody in serum | Immunogen-specific antibody in MEF |
|--------------|-------------------------------------|----------------------------------|
| LB1          | 40 IgG 40 IgA                        | 20 IgG 10 IgA                    |
| LB1 + dmLT   | 160* IgG 20 IgA                      | 80 IgG 40 IgA                    |
| rsPilA       | 80 IgG 20 IgA                        | 20 IgG 10 IgA                    |
| rsPilA + dmLT| 320* IgG 40 IgA                      | 160* IgG 20 IgA                  |
| chimV4       | 40 IgG 20 IgA                        | 40 IgG 10 IgA                    |
| chimV4 + dmLT| 640* IgG 160* IgA                    | 320* IgG 20 IgA                  |

**Abbreviations:** dmLT, double mutant of *E. coli* heat-labile enterotoxin; Ig, immunoglobulin; MEF, middle ear fluid; rsPilA, recombinant soluble PilA; TCI, transcutaneous immunization. *P<0.05 compared with respective immunogen-only titer.
the tympanic membranes of animals first challenged with NTHI and then immunized with chimV4 + dmLT, each a statistically significant result compared with that obtained following immunization with dmLT alone ($P < 0.05$). Unlike our observations for biomass reduction alone, wherein we were unable to detect the influence of dmLT, here our data showed a greater reduction in signs of OM after TCI with any of the three immunogens admixed with dmLT, compared with immunogen alone. Therefore, TCI after direct challenge of the middle ear resulted in resolution of signs of ongoing NTHI-induced OM in addition to mediating a marked reduction in resident biomass within the middle ear.

Migration of DCs from the pinnae

Last, we examined the migration of DCs from the pinna after TCI to identify potential sites of immune induction after immunization by this route. To do so, the amine-reactive dye carboxyfluorescein succinimidyl ester (CFSE) was applied to the pinnae along with each vaccine formulation to allow for discrimination among cells resident within lymphoid tissues and DCs that had migrated to these sites from the pinnae. We observed that within 1 h after TCI, only 13.6% of cells isolated from the nasal-associated lymphoid tissue (NALT) of animals immunized with adjuvant alone were CFSE$^+$ CD11c$^+$ (Figure 6a). In contrast, TCI with either rsPilA, LB1, or chimV4 each delivered with dmLT resulted in a 2.5- to 5.4-fold relative increase (37.2, 34.4, and 72.9%, respectively) in the percentage of CFSE$^+$ DCs detected within this lymphoid aggregate (Figure 6b–d). CFSE$^+$ CD11c$^+$ DCs were also detected in the axillary and brachial lymph nodes, although only 1.1- to 2.0-fold more CFSE$^+$ DCs were observed in lymph nodes after TCI with any immunogen vs. the adjuvant alone (data not shown).

No difference in the percentage of CFSE$^+$ CD11c$^+$ DCs within the cervical or mediastinal lymph nodes or spleen of animals that received an immunogen and those immunized with dmLT alone was found at this time point. These data suggested that DCs within the pinnae sampled the NTHI adhesin-derived immunogens that had been applied to the surface of the pinnae and were induced to mature. DC maturation resulted in the preferential migration of these cells to primarily the NALT, and also the axillary and brachial lymph nodes.

Further analysis was performed to distinguish between the DC types that migrated to the lymphoid tissues. We specifically focused on discrimination between Langerhan's cells vs. dermal DCs, the primary antigen-presenting cells found within the skin. A total of ~69% of CFSE$^+$ cells within the NALT were positively
labeled with antibody directed against dendritic cell-specific intercellular adhesion molecule-3 grabbing integrin (DC-SIGN), specific for dermal DCs,\textsuperscript{27} as opposed to 0.3\% of cells that labeled positively for CD207, which is selectively expressed by Langerhan’s cells\textsuperscript{28} (Figure 6e). Therefore, these data indicated that the primary antigen-presenting cells involved in induction of the immune responses observed herein were DCs.

To further confirm that the positive signal described above was because of the migration of DCs to lymphoid tissues and not because of diffusion of the dye alone through the lymphatics to that site, we labeled bone marrow-derived DCs with CFSE, activated them with chimV4 + dmLT or dmLT alone \textit{in vitro}, and then injected the DCs intradermally into the pinnae. After 1 h, a population of CFSE\textsuperscript{+} cells was detected within the NALT after receipt of DCs activated with chimV4 + dmLT (Figure 6f), but not when activated with dmLT alone (Figure 6f, inset). Moreover, 4.3\% of the cells isolated from the NALT were CFSE\textsuperscript{+}, whereas $\approx 0.6\%$ was observed within the cervical, axillary, and brachial lymph nodes and spleen (data not shown). Thus, the migration of DCs resident within the pinnae after TCI and those instilled into the pinnae after \textit{in vitro} activation were similar, a result that suggested preferential homing to this local lymphoid aggregate as mediated via local cytokine/chemokine signals. Collectively, our tracking data demonstrated that immunogen-activated DCs within the pinnae migrated primarily to a proximal lymphoid aggregate, the NALT. Moreover, the cell type activated after TCI was the dermal DC, which likely had a critical role in the initiation of the protective immune response observed herein.

**DISCUSSION**

OM is a prevalent disease of children worldwide, and although commonly managed by prescription of antibiotics and surgical intervention where available, the incidence and cost attributed to this disease is substantial.\textsuperscript{2} Moreover, the emergence of multiple antibiotic-resistant bacteria, including strains of NTHI, is a cause for concern.\textsuperscript{29} Thus, immunization against OM has the potential to alleviate this socioeconomic burden by prevention or resolution of disease. At present, a licensed 10-valent pneumococcal capsular conjugate vaccine wherein NTHI protein D serves as a carrier molecule (Synflorix, GlaxoSmithKline, Rixensart, Belgium) has demonstrated 35.3\% protective efficacy against NTHI-induced OM after parenteral immunization of children in a clinical trial in Slovakia and the Czech Republic.\textsuperscript{30} Although shown as a secondary outcome measure, this trial nonetheless demonstrated, for the first time, that parenteral delivery of a NTHI-derived antigen could provide protection against OM due to NTHI. To increase the modest coverage observed against NTHI-induced OM, examination of additional NTHI-specific targets is needed.

We have focused our vaccine development efforts on two of multiple adhesins expressed by NTHI, OMP P5 and Tfp, and recently utilized an established chinchilla model of viral-bacterial superinfection shown to be predictive of the aforementioned clinical trial outcome.\textsuperscript{7,31} Collectively, these preclinical data demonstrated that antibody induced by parenteral immunization with NTHI OMP P5- and Tfp-derived vaccine candidates (called LB1, rsPiIA, and chimV4) provides significant protection against experimental NTHI-induced OM.\textsuperscript{6} We now sought to expand our vaccine delivery routes to include noninvasive administration regimens. Currently, children in the United States receive up to 25 vaccines by injection during the first 2 years of life.\textsuperscript{32} This can be cause for concern by parents who may ultimately delay or refuse immunization of their child. Also, although not of considerable concern in developed countries, the reuse of needles in developing countries poses serious risk for transmission of blood-borne diseases.\textsuperscript{33,34} Thus, although vaccination by injection is proven to be extremely effective as a preventative intervention, development of alternative delivery strategies for current or future formulations could potentially serve as equally effective means to induce protective immunity while simultaneously addressing bottlenecks associated with injectable vaccines.

TCI is a simple and noninvasive method for vaccine administration. In addition to the ease of delivery, both systemic and mucosal immunity is induced by this regimen. OM is a disease of the uppermost respiratory tract mucosa, and thus the potential to initiate mucosal immunity, particularly in the nasopharynx where NTHI normally reside, holds promise to limit or prevent its onset. We focused on the chinchilla pinnae as an easily accessible site for administration that did not require manipulation, such as shaving, before delivery. Moreover, as there is greater appreciation for compartmentalization within the mucosal immune system because of homing of immune cells that results in the most powerful response induced at the site proximal to delivery,\textsuperscript{35,36} we wanted to favor development of an immune response in proximity to the NP and middle ear. This premise is supported by work in a murine host, where after TCI, the greatest cytotoxic lymphocyte activity was detected by cells isolated from lymphoid tissues in close proximity to site of administration whereas less activity was observed by cells from distal tissues.\textsuperscript{11}

A proof-of-concept study demonstrated that TCI induced an immunogen-specific immune response in the chinchilla host, and that bilateral (both pinnae) administration induced more robust immunity compared with unilateral delivery (one pinna; data not shown). Furthermore, upon challenge with NTHI, we observed clearance of NTHI from the NP and middle ear. Herein, we expanded upon that preliminary study to examine the protection afforded by TCI with the OMP P5-derived candidate LB1, the Tfp-directed candidate rsPiIA, and the chimeric OMP P5- plus Tfp-directed immunogen chimV4 when delivered with dmLT, a potent adjuvant.

Our current data demonstrated that TCI before NTHI challenge with any of the three immunogens induced the production of both immunogen-specific IgA and IgG and although clearance of NTHI was associated with the production of both antibody isotypes, a greater relative quantity of IgG was consistently observed. NTHI possess the \textit{iga} gene that encodes an IgA1 protease, and up to a third of strains have an additional gene (\textit{igaB}) that encodes a second IgA protease.\textsuperscript{37,38} Whereas IgA is the conventional antibody isotype detected at mucosal
surfaces, mucosal IgG, either produced locally or present via transudation from serum, is also known to contribute to protection against mucosal infection. We observed a correlation between antibody GMT of ≥160 and enhanced resolution of disease after TCI via use of a preventative or therapeutic regimen. Protection against NTHI-induced OM is primarily antibody mediated, although the contribution of T-cell-mediated mechanism cannot be ruled out, as it is required for clearance of NTHI from the rat lung. The data presented herein demonstrated that TCI induced the production of antibodies that targeted adhesins expressed by NTHI and, as such, was likely the primary mechanism for eradication of the bacterium from the nasopharynx and middle ear.

TCI before bacterial challenge with rsPilA, LB1, or chimV4 delivered with dmLT resulted in a rapid reduction in the bacterial load of NTHI within the NP of immune chinchillas, in addition to a reduction in the percentage of culture-positive animals per cohort, compared with receipt of immunogen or adjuvant alone. Within middle ears, whereas an increase in bacterial concentration is typically observed after direct challenge because of initial bacterial replication, only a modest initial increase in CFU NTHI was observed in cohorts that received any of the three immunogens plus dmLT and was followed by a rapid elimination of bacteria from the middle ear. These data clearly demonstrated that TCI with OMP P5 or Tfp-targeted immunogens with dmLT induced an efficacious immune response. Among these three cohorts, differences were observed specific to the time to clear NTHI from the NP and middle ear after challenge. It is known that OMP P5 is constitutively expressed and is important for enabling NTHI to establish colonization in the NP. NTHI Tfp are temporally expressed and necessary for NTHI to maintain long-term colonization at this site. Moreover, these adhesins are utilized for both adherence and biofilm formation within the middle ear. Thus, the presence of antibody specific to each adhesin, or both adhesins, likely served to prevent NTHI adherence, which facilitated elimination of NTHI from the NP and middle ear upon challenge.

OM can be a chronic and/or recurrent disease, a consequence of biofilms established by NTHI within the middle ear. Based on the efficacy afforded by immunization with the OMP P5- and Tfp-targeted immunogens before bacterial challenge, we wondered whether TCI after NTHI challenge might also effectively resolve OM by eradicating an already established NTHI biofilm from the middle ear. Immunization via a therapeutic regimen resulted in a reduction in the signs of OM based on a clinically relevant scoring system, in addition to overall resolution of an established NTHI biomass in the middle ear as determined by blinded gross examination of the middle ear space. Whereas a significant reduction in biomass was grossly observed for all immune animals compared with those that received dmLT alone, only cohorts that received rsPilA or chimV4 admixed with dmLT demonstrated a significant reduction in signs of disease as determined by video otoscopy and tympanometry. The two techniques, one of gross examination and the other of observation for signs of disease, do not discredit each other. Rather, they indicated that whereas TCI via a therapeutic route resulted in reduction of middle ear biomass, MEFs had yet to drain through the Eustachian tube or be absorbed by the middle ear mucosa in all animals, although overall signs of OM were reduced. Therapeutic vaccines for control of other viral or bacterial infections have been examined in experimental and clinical trials with promising results, and currently in use is a therapeutic canine melanoma vaccine to combat oral melanoma. Thus, the strategy to resolve active disease by therapeutic vaccination is promising.

An additional observation from each study presented herein was the enhanced immune response and resultant bacterial clearance by formulation of each immunogen with dmLT, compared with administration of immunogen alone. Derivatives of cholera toxin and E. coli heat-labile enterotoxin have shown utility as adjuvants for mucosal and cutaneous immunization regimens, wherein the toxicity associated with mucosal application of each holotoxin is not observed. Specific to dmLT, the engineered amino-acid substitutions at position 192 inactivates a trypsin cleavage site and at position 211 modifies a potential pepsin cleavage site. The resultant molecule is insensitive to proteolysis by either enzyme, as by design. Furthermore, no toxicity is observed in a patent mouse enterotoxicity model. Although the exact mechanism is undefined, it is believed that adjuvant activity is an overall outcome of the activation of various cell types, including DCs.

We also examined the role of cutaneous DCs in the observed rapid and protective immune response. Our data demonstrated that TCI with the OMP P5- and Tfp-targeted immunogens delivered with dmLT induced the maturation and subsequent migration of DCs resident within the pinnae, a response not observed after application of dmLT alone. As a complimentary approach, DCs activated in vivo and then injected subdermally into the pinnae exhibited similar maturation and migration characteristics as in vivo-activated DCs. By each approach, immunogen-activated DCs migrated primarily to the NALT, an immune inductive site, likely because of local cytokine/chemokine signaling. Migratory cells within the NALT were identified to be predominantly dermal DCs, not Langerhan’s cells, based on the expression of DC-SIGN vs. CD207. Although not completely defined, it is proposed that Langerhan’s cells are responsible for tolerogenic immunity, i.e., to self-antigens, whereas dermal DCs are involved in development of protective immunity. Moreover, compared with Langerhan’s cells, dermal DCs exhibit faster migration and populate lymph nodes in areas closer to B-cell follicles, facilitating antigen presentation to B cells and initiation of immune responses. Therefore, TCI served to engage dermal DCs within the chinchilla pinnae that facilitated the development of a local and systemic immune response. We continue to examine the contribution of additional innate immune effector to the rapid resolution observed herein.

As we continue to develop TCI as a delivery method, it is important to consider the practical application of this method to humans, particularly to very young children. To promote development of a mucosal immune response in the uppermost airway of a child, it is rational to propose vaccine application to skin behind the ear or back of the neck. There is evidence that
of the Waldeyer's tonsillar ring in the neck and pharynx functions similar to the rodent NALT, and thus the potential exists to induce an immune response within lymphoid tissues proximal to the human nasopharynx and middle ear, as desired. Furthermore, to facilitate widespread application, the TCI method must be simple and inexpensive, preferably deviceless, and yet be able to efficiently deliver the formulation to the dermal DCs through the stratum corneum. Whereas there are multiple strategies in development to breach this protective barrier,\textsuperscript{51} we suggest that direct application of a gel or cream on to the skin also has the potential to hydrate the stratum corneum, restrict diffusion of the antigen, and promote long-term sampling by DCs.

In summary, TCI served to engage dermal DCs within the chinchilla pinnae that resulted in the development of a local mucosal, in addition to systemic, immune response. Administration of the NTHI OMP P5- and Tfp-directed immunogens admixed with dmLT was efficacious to both prevent experimental NTHI-induced OM and to resolve active OM. These data therefore demonstrated that TCI is an effective way to immunize against experimental NTHI-induced OM and has potential application to prevent other diseases of the respiratory tract due to NTHI. Moreover, the reduced costs associated with noninvasive routes of immunization such as TCI hold great promise in terms of expanding the use of vaccines to prevent OM beyond the boundaries of developed countries.

Immunogens and adjuvant

NTHI OMP P5 was observed expressed by 100\% of a panel of middle ear and nasopharyngeal NTHI isolates collected from children with chronic OM.\textsuperscript{53} Multiple analytical analyses of the deduced amino-acid sequence of OMP P5 predict four surface-exposed regions within the N-terminus of this adhesin,\textsuperscript{53,54} and within the third surface-exposed region is a 19-mer B-cell epitope that is incorporated into LB1.\textsuperscript{55} Among NTHI strains tested, there is limited amino-acid sequence diversity within this moiety that allows for segregation of isolates into three groups, 76\% of which cluster into one majority group. The immunogen LB1 is a 40-mer synthetic chimeric peptide comprising the aforementioned 19-mer B-cell epitope from OMP P5 that is colinearly synthesized with the aforementioned 19-mer B-cell epitope described within the immunogen LB1.\textsuperscript{6} A double mutant form of \textit{E. coli} heat-labile enterotoxin, called LT(R192G-L211A) and abbreviated dmLT, wherein glycine is substituted for arginine at position 192 and alanine is substituted for lysine at position 211, served as the adjuvant.\textsuperscript{16} The amino-acid substitutions render dmLT nontoxic while maintaining its adjuvant properties.

**NTHI strain**

NTHI strain 86-028NP was isolated from the nasopharynx of a child undergoing tympanostomy and tube insertion for chronic OM at Nationwide Children's Hospital, Columbus, OH. This strain has been characterized and extensively used in chinchilla models of OM and a rat model of pulmonary clearance.\textsuperscript{5,24,31,57}

**Immunization via a preventative regimen and NTHI challenge**

TCI via a preventative immunization regimen was performed as follows: both pinnae of each alert animal were hydrated for 5 min by placement of a gauze soaked in sterile, pyrogen-free 0.9\% sodium chloride (Hospira, Lake Forest, IL) on the inner surface before vaccination. The inner surface of each pinna was then blotted with dry gauze and 50\\mu l of each vaccine formulation was applied using a pipet. The pinnae were then folded in half and opposing surfaces gently rubbed together. Formulations consisted of 10\mu g LB1, rsPilA, or chimV4 delivered alone or admixed with 10\mu g LT(R192G-L211A), also called “dmLT”, or 10\mu g dmLT alone. Two doses were delivered at weekly intervals. NTHI challenge was performed as previously described.\textsuperscript{54} Briefly, at 1 week after receipt of the second immunizing dose, all chinchillas were challenged intranasally with 10\textsuperscript{8} CFU NTHI strain 86-028NP delivered in 0.2 ml pyrogen-free saline divided equally between the nares, as well as transbulbarly with 1,000 CFU NTHI delivered in 0.3 ml sterile pyrogen-free saline per bulla. Challenge doses were confirmed by plate count.

**NTHI challenge and immunization via a therapeutic strategy**

TCI following a therapeutic regimen involved challenge of all chinchillas exclusively transbullarly with 1,000 CFU NTHI strain 86-028NP before immunization. At 4 days after NTHI challenge, animals were immunized by TCI as described above. Formulations consisted of 10\mu g LB1, rsPilA, or chimV4 delivered alone or admixed with 10\mu g dmLT or 10\mu g dmLT alone and were delivered twice at weekly intervals. At 1 week after receipt of the second immunizing dose, all animals were killed.

**Histology of chinchilla pinnae**

Pinnae were collected and trimmed to the central 2.5 mm\textsuperscript{2} portion. The pinna was then cut into four strips of equal size and fixed in 2\% w/v paraformaldehyde in 0.1 \textit{m} phosphate buffer, pH 7.4, for 24 h. Strips were processed for routine histology and embedded in paraffin. Serial sections (5 \textmu m) were cut and tissue stained with hematoxylin and eosin.

**Collection of blood and mucosal secretions**

Blood for serum was collected via cardiac puncture before immunization (pre) and 1 week after receipt of the second immunizing dose (immune) for all animals immunized via a preventative regimen. Animals immunized via a therapeutic regimen were bled before NTHI challenge and at study end.

NP lavages were performed on animals immunized via a preventative regimen before immunization (pre) and 1 week after receipt of the second immunizing dose (immune) for all animals immunized via a preventative regimen. Animals immunized via a therapeutic regimen were bled before NTHI challenge and at study end.

Video otoscopy (using a 0\textdegree, 3-inch probe connected to a digital camera system) to monitor signs of tympanic membrane inflammation and/or presence of fluid within the middle ear space was performed and overall signs of OM were rated on a scale of 0 to 4+ as previously described.\textsuperscript{2,24,31} Middle ears with a score of $\geq 2.0$ were always considered positive for OM as MEF is visible behind the tympanic membrane. Each middle ear was...
considered independent, and for each cohort, the percentage of middle ears with OM was calculated.

Epitheatrical taps to retrieve middle ear effusions were performed on any chinchilla whose tympanic membrane was ranked as ≥2.5 on a scale of 0 to +4.0. Epitheatrical taps were not performed on ears ranked 2.0, due potential for perforation of the tympanic membrane to retrieve the low volume of MEF. NP lavage and MEFs were serially diluted and plated onto chocolate agar supplemented with 15 μg ampicillin per ml medium or chocolate agar, respectively, to semiquantitate CFU NTHI per ml fluid type. The mean CFU NTHI per ml fluid was reported for each cohort.

Evaluation of middle ear biomass
Upon killing of animals immunized after NTHI challenge, the inferior bullae from each animal were dissected, opened to reveal the middle ear space, and washed with 1 ml sterile, pyrogen-free saline to remove residual MEF and loosely adherent biomass. The bullae and remaining adherent biomass were then imaged with a digital camera. The images from the left and right bulla were scrambled and scored by nine blinded observers who ranked the relative residual biomass on a 0 to +4 scale, wherein 0 = no biomass; 1 = biomass fills <25% of middle ear space; 2 = biomass fills 25–50% of middle ear space; 3 = biomass fills 50–75% of middle ear space; and 4 = biomass fill 75–100% of middle ear space. The mean biomass score for each bulla was reported.

Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay was performed on serum to detect immunogen-specific IgG and IgA in immune serum and MEFs. Samples were incubated in LB1-, rsPiLA-, or chimV4-coated wells (0.2 μg protein per well) for 3 h at 25°C and antibody was detected with horseradish peroxidase-conjugated goat anti-rat IgG or IgA (Bethyl Laboratories, Montgomery, TX). Color was developed with 3,3',5,5'-tetramethylbenzidine (Pierce Biotechnology, Rockford, IL). Reciprocal titers were defined as the dilution that yielded an OD405nm value of 0.1 above control wells that were incubated without sample fluids. Assays were performed a minimum of three times and reciprocal titers reported as the GMT.

Flow cytometry to detect recognition of native proteins on NTHI
To detect the recognition of native OMP P5 and Tfp as expressed on the surface of NTHI by antibodies in NPlavage fluids, flow cytometric analysis was performed. NTHI strain 86-028NP was cultured overnight in vitro to facilitate the diffusion of the dye within the lymphatics, we investigated whether in vitro-activated, bone marrow-derived DCs would similarly follow homing signals to the NALT when applied to the pinnae. Thus, chinchilla bone marrow cells were harvested and cultured in the presence of 40 ng each of human recombinant granulocyte-macrophage colony-stimulating factor and interleukin-4 (R&D Systems) per ml to induce differentiation of precursor cells as previously described. After 6 days, the immature DCs were labeled with 10 μM CFSE before incubation for 30 min with either 10 μg rhimV4 plus 10 μg dmTL or 10 μg dmTL alone. The treated DCs were washed to remove unbound immunogen, adjusted to 10^6 cells per 100 μl, and injected intradermally to alert chinchillas in a volume of 50 μl per pinna. The animals were killed 1 h later, and the lymphoid tissues were processed as described above. CFSE^+ cells were detected by flow cytometry. A total of 10,000 viable events were collected for each of three independent assays and representative plots are shown.

Statistics
Statistical differences between antibody titers, bacterial counts in NP lavage fluids, and MEFs were determined using Kruskal–Wallis one-way analysis of variance on ranks and Dunn’s method for multiple comparisons. A P-value of ≤0.05 was considered significant. Significant differences in relative biomass among cohorts and percentage of middle ears with OM were assessed by a repeated measures analysis of variance and Bonferroni’s multiple comparison test. A P-value of ≤0.05 was considered significant.

ACKNOWLEDGMENTS
This work was supported by R01 DC003915 and DC007464 to L.O.B. We thank Glen McGillivary, Amanda Dickson, Joseph Jurcisek, and Dana Staffen for technical assistance, Dr Santiago Partida-Sanchez for dendritic cell experimental design, and Jennifer Neelans for article preparation.

DISCLOSURE
The authors declared no conflict of interest.
Vogt, A. et al. Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans. J. Immunol. 180, 1482–1489 (2008).

Döller-Hagen, J. E. et al. Transcutaneous immunization with toxin-coregulated pilin A induces protective immunity against Vibrio cholerae O1 El Tor challenge in mice. Infect. Immun. 74, 5834–5839 (2006).

Ghose, O. et al. Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. Infect. Immun. 75, 2826–2832 (2007).

Skountzou, I., Guan, F.S., Jacob, J., Compans, R.W. & Kang, S.M. Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine 24, 6110–6119 (2006).

Summerton, N.A. et al. Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine 28, 1404–1411 (2010).

Misra, D., Mishra, P.K., Dubey, V., Nahar, M., Dabadghao, S. & Jain, N.K. Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigen-loaded modified liposomes. Eur. J. Pharm. Sci. 33, 424–433 (2008).

Murphy, T.F., Bakaletz, L.O. & SMEesters, P.R. Microbial interactions in the respiratory tract. Pediatr. Infect. Dis. J. 28 (10 Suppl), S121–S126 (2009).

Hall-Stoodley, L. et al. Direct detection of bacterial biofilms on the middle-ear mucus of children with chronic otitis media. JAMA 296, 202–211 (2006).

Ehrlich, G.D. et al. Mucosal biofilm formation on middle-ear mucus in the chinchilla model of otitis media. JAMA 287, 1710–1715 (2002).

Gallagher, T.K., Wu, S., Webster, P. & Aguilera, R. Identification of biofilm proteins in non-typeable Haemophilus influenzae. BMC Microbiol. 6, 65 (2006).

Jurcisek, J.A. & Bakaletz, L.O. Biofilms formed by nontypeable Haemophilus influenzae in vivo contain both double-stranded DNA and type IV pilin protein. J. Bacteriol. 189, 3868–3875 (2007).

Tan, G. et al. Hydration effects on skin microstructure as probed by high-resolution cross-polarized electron microscopy and mechanistic implications to enhanced transcutaneous delivery of biomacromolecules. J. Pharm. Sci. 99, 730–740 (2010).

Bakaletz, L.O., Kennedy, B.J., Novotny, L.A., Duquesne, G., Cohen, J. & Lobet, Y. Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection. Infect. Immun. 67, 2746–2762 (1999).

Legge, K.L. & Braciale, T.J. Accelerated migration of respiratory dendritic cells to the regional lymph nodes is limited to the early phase of pulmonary infection. Immunity 18, 265–277 (2003).

Novotny, L.A., Partida-Sanchez, S., Munson, R.S. Jr & Bakaletz, L.O. Differential uptake and processing of a Haemophilus influenzae P5-derived immunogen by chinchilla dendritic cells. Infect. Immun. 76, 967–977 (2008).

Geijtenbeek, T.B. et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 100, 575–585 (2000).

Valladeau, J. et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 12, 71–81 (2000).
53. Duim, B., Bowler, L.D., Eijk, P.P., Jansen, H.M., Dankert, J. & van Alphen, L. Molecular variation in the major outer membrane protein P5 gene of nonencapsulated *Haemophilus influenzae* during chronic infections. *Infect. Immun.* **65**, 1351–1356 (1997).

54. Webb, D.C. & Cripps, A.W. Secondary structure and molecular analysis of interstrain variability in the P5 outer-membrane protein of non-typable *Haemophilus influenzae* isolated from diverse anatomical sites. *J. Med. Microbiol.* **47**, 1059–1067 (1998).

55. Bakaletz, L.O., Leake, E.R., Billy, J.M. & Kaumaya, P.T. Relative immunogenicity and efficacy of two synthetic chimeric peptides of fimbria as vaccinogens against nasopharyngeal colonization by nontypeable *Haemophilus influenzae* in the chinchilla. *Vaccine* **15**, 955–961 (1997).

56. Bakaletz, L.O. *et al.* Demonstration of type IV pilus expression and a twitching phenotype by *Haemophilus influenzae*. *Infect. Immun.* **73**, 1635–1643 (2005).

57. Kyd, J.M., Cripps, A.W., Novotny, L.A. & Bakaletz, L.O. Efficacy of the 26-kilodalton outer membrane protein and two P5 fimbriin-derived immunogens to induce clearance of nontypeable *Haemophilus influenzae* from the rat middle ear and lungs as well as from the chinchilla middle ear and nasopharynx. *Infect. Immun.* **71**, 4691–4699 (2003).

This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit [http://creativecommons.org/licenses/by-nc-nd/3.0/](http://creativecommons.org/licenses/by-nc-nd/3.0/)